Slon-Campos, Jose Luis
Dejnirattisai, Wanwisa
Jagger, Brett W.
López-Camacho, César http://orcid.org/0000-0001-7932-2341
Wongwiwat, Wiyada
Durnell, Lorellin A.
Winkler, Emma S.
Chen, Rita E.
Reyes-Sandoval, Arturo http://orcid.org/0000-0002-2648-1696
Rey, Felix A.
Diamond, Michael S. http://orcid.org/0000-0002-8791-3165
Mongkolsapaya, Juthathip http://orcid.org/0000-0003-3416-9480
Screaton, Gavin R. http://orcid.org/0000-0002-3549-4309
Funding for this research was provided by:
Wellcome Trust (203224/Z/16/Z, 095541/A/11/Z, 203224/Z/16/Z)
U.S. Department of Health & Human Services | National Institutes of Health (T32 AI007172, R01 AI073755, R01 AI127828, R01 HD091218)
UK Department of Health and Social Care
French Government’s Investissement d’Avenir Programme (Labex Integrative Biology of Emerging Infectious Diseases, IBEID, grant ANR-10-LABX-62-IBEID 4E AAP
MRC-Newton fund
Article History
Received: 6 June 2019
Accepted: 22 July 2019
First Online: 2 September 2019
Competing interests
: G.R.S., F.A.R. and J.M. are named inventors on a patent owned by Imperial College London and Institut Pasteur describing the EDE and its use as a potential immunogen (application number EP3172229A1). G.R.S. sits on the advisory board of GSK Vaccines. M.S.D. is a consultant for Inbios and Atreca, and sits on the Scientific Advisory Board at Moderna. The remaining authors declare no competing interests.
Free to read: This content has been made available to all.